Ray Therapeutics received EMA PRIME designation for its RTx-015 optogenetic gene therapy for retinitis pigmentosa, following recent FDA RMAT status. The company also appointed Michael Murtagh as Chief Regulatory Officer to support global development.
Oncotelic Therapeutics announced expanded international intellectual property coverage for OT-101 across neurology, oncology and CNS drug-delivery technologies. The company also highlighted biotech valuation trends tied to clinical progress and its 45% stake in GMP Bio.
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
The global advanced drug delivery systems market is projected to grow from $255 billion in 2024 to $439.7 billion by 2034 at a 5.6% CAGR. Cardiovascular disease applications dominate with 37.8% market share, while North America leads regionally with 41.3% of the market. Emerging technologies include 3D-printed drug implants, smart hydrogels, and magnetic nanofiber platforms.
Origin Genomics launches to pursue germline gene editing research despite US prohibitions, while Thermo Fisher completes its $8.88 billion acquisition of Clario Holdings. Lucid Diagnostics reports Q4 revenue growth, and multiple partnerships form across the diagnostics and synthetic biology sectors.
Monash University and Ono Pharmaceutical have signed two licence agreements for the development of anti-GPCR antibodies targeting autoimmune and inflammatory diseases. The agreements result from Ono exercising options on research collaborations announced in 2023. The partnership combines Monash's research excellence with Ono's drug development capabilities to address unmet medical needs.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07508670 |
An Observational Study of the NeuroBell EEG Monitor |
COMPLETED | |
| NCT07374393 |
Establishment of a Sleep and Sleep-disorder Research Cohort in Patients With Neurological Disorders |
ENROLLING_BY_INVITATION | |
| NCT07344792 |
Physician Diagnosis of Neurologic Cases With Large Language Models |
COMPLETED | NA |
| NCT07014982 |
Remote Assessment of Digital Neurologic Testing |
NOT_YET_RECRUITING | NA |
| NCT06952829 |
Evaluation of A-DIVA Score Effectiveness at Admission for Preserving Venous Capital in Patients With Difficult Access |
NOT_YET_RECRUITING | NA |
| NCT06921590 |
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06856902 |
BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe |
RECRUITING | NA |
| NCT06779292 |
Application of Large Language Models in Emergency Neurology |
COMPLETED | |
| NCT06539260 |
Clinical Relationship Between Vitamin D-mediated Th17 and Treg Cells and Parkinson's Disease |
COMPLETED | EARLY_PHASE1 |
| NCT05539196 |
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications |
RECRUITING |
